Sonus Pharmaceuticals

Sonus is developing a number of potential product candidates for the treatment of cancer using its proprietary TOCOSOL drug delivery system, a vitamin-E based emulsion technology. The development of cancer therapeutics with the TOCOSOL technology may result in products that can be delivered more safely and effectively. The Company's lead product is TOCOSOL Paclitaxel, a novel formulation of paclitaxel, one of the most widely prescribed cancer drugs on the market today. The product offers the convenience of a ready-to-use formulation, which does not require reconstitution, dilution or preparation as is required with the marketed paclitaxel products. In clinical trials to date, TOCOSOL Paclitaxel is demonstrating promising safety and anti-tumor activity in cancer patients who have failed prior chemotherapeutic regimens. The product appears to be well tolerated by patients and is given in a short 15-minute infusion compared to the prolonged three-hour infusion required with available paclitaxel products. With patient enrollment complete in the Phase 2a clinical program for TOCOSOL Paclitaxel, Sonus has initiated additional clinical studies to provide data that will be the basis for new drug applications submitted to the U.S. Food and Drug Administration and other regulatory authorities around the world.